{"url_path":"/sec/bcli/8-k/2026-05-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1137883/0001104659-26-062766-index.html","accession_number":"0001104659-26-062766","cik":"0001137883","ticker":"BCLI","issuer_name":"BRAINSTORM CELL THERAPEUTICS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1137883/0001104659-26-062766-index.html","primary_entity_key":"0001137883","primary_entity_name":"BRAINSTORM CELL THERAPEUTICS INC."},"word_count":86,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n*(d) Exhibits.*\n\n \n\n**Exhibit No.**\n \n**Description**\n\n[99.1](tm2614771d1_ex99-1.htm)\n \n[Press\nRelease issued by Brainstorm Cell Therapeutics Inc. on May 15, 2026.](tm2614771d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**BRAINSTORM CELL THERAPEUTICS INC.**\n\n \n \n \n\nDate: May 15, 2026\nBy:\n/s/ Chaim Lebovits\n\n \n \nChaim Lebovits\n\n \n \nPresident and Chief Executive Officer"}